Evidence map›Paper›PMID 42569313›Full record

ArticleContemporary clinical trials communications2026

Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry.

Channing J Paller, Ken Freitas, Natalie Macario, Christina Tran, Kelly Faville, Kathy Wiedemer, Jenny Chiang, Justin Lorentz, Leonard J Appleman, Andrew J Armstrong and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Channing J PallerJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Ken FreitasAdvancing Cancer Treatment, McLean, Virginia, USA.
Natalie MacarioProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Christina TranProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Kelly FavilleAdvancing Cancer Treatment, McLean, Virginia, USA.
Kathy WiedemerAdvancing Cancer Treatment, McLean, Virginia, USA.
Jenny ChiangAdvancing Cancer Treatment, McLean, Virginia, USA.
Justin LorentzSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Leonard J ApplemanUniversity of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA.
Andrew J ArmstrongDuke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.
Pedro C BarataUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Hala T BornoTrial Library, San Francisco, CA, USA.
Keith CrawfordProstate Health Education Network Inc., Quincy, MA, USA.
Tiffani A DeMarcoInova Schar Cancer Institute, Fairfax, VA, USA.
Robert DreicerUniversity of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA.
Jo Ann B ElrodSeattle Cancer Care Alliance, Seattle, WA, USA.
Sheryl GabramGeorgia Center for Oncology Research and Education, Atlanta, GA, USA.
Christopher GeorgeRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Elisabeth I HeathDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Arif HussainUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Maha H A HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Jordan M NeilTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK, USA.
Shifeng MaoAllegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Rana R McKayUniversity of California San Diego, La Jolla, CA, USA.
Alicia K MorgansLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Motolani E OgunsanyaTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK, USA.
Matthew OrtonIndiana University Health Arnett Cancer Center, Lafayette, IN, USA.
Ted RitchieUrology Clinics of North Texas, Dallas, TX, USA.
Biren SaraiyaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Alexandra O SokolovaOregon Health & Science University Knight Cancer Institute, Portland, OR, USA.
Russell SzmulewitzUniversity of Chicago, Chicago, IL, USA.
Imani ForttProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Leezandra RamosProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Stormi SmithProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Patrick FreemanProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Amanda McMannisProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Rebecca GreenProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Jacob VinsonProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Heather H ChengUniversity of Washington, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The PROMISE Registry is a U.S. decentralized, 20-year prospective prostate cancer germline genetic registry. Here, we examine the effectiveness of different recruitment strategies, including institutional partnerships, direct-to-patient marketing outreach, and community engagement grants (CEGs). Methods: Recruitment efforts were categorized into: (1) Institutional outreach through physician referrals, (2) Direct-to-patient marketing outreach, through online vehicles, including a PROMISE website and sponsored content, webinars, media relations, and other efforts to drive traffic to this site. Events and conferences were used on a limited basis, and (3) CEGs supported local organizations in reaching disproportionately affected populations. Effectiveness of each category was assessed through enrollment data, demographic diversity, and overall cost. Results: From May 2021 to December 2024, 5649 individuals enrolled. Marketing outreach ​accounted for 61% of enrollment compared to other outreach methods. Non-White and Hispanic individuals consisted of 9.4% and 2.3%, of all consented participants, respectively. Almost one-fifth (19%) of participants enrolled were estimated to face greater levels of disadvantage, as defined by the Area Deprivation Index (ADI). Conclusion: A multifaceted recruitment approach was key to exceeding recruitment goals. Online marketing and strategic partnerships with patient advocacy organizations were effective and impactful. Opportunities for future research may explore refinements in digital outreach and ways to overcome accessibility barriers to improve rates of engagement and proportional representation in clinical registries.

Identifiers

PMID42569313
PMCPMC13449659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.